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Abstract
XMRV is a gammaretrovirus associated in some studies with human prostate cancer and chronic fatigue syndrome.
Central to the hypothesis of XMRV as a human pathogen is the description of integration sites in DNA from
prostate tumour tissues. Here we demonstrate that 2 of 14 patient-derived sites are identical to sites cloned in the
same laboratory from experimentally infected DU145 cells. Identical integration sites have never previously been
described in any retrovirus infection. We propose that the patient-derived sites are the result of PCR contamination.
This observation further undermines the notion that XMRV is a genuine human pathogen.
Introduction
XMRV was originally described in 2006 in the tumour
tissue of patients with a familial form of prostate cancer
associated with mutations that impair the function of
the antiviral defence protein RNase L [1]. Three inde-
pendent groups subsequently reported the presence of
XMRV in a significant proportion of prostate cancers,
but the linkage to polymorphisms of the RNase L gene
was not confirmed. In contrast, at least seven other stu-
dies have reported an inability to detect, or extremely
low prevalence of, XMRV in prostate cancer despite
using highly sensitive PCR-based assays.
Immunohistological, in situ-hybridisation and serologi-
cal studies have also been inconsistent in their findings.
Some studies [1,2], using immunostaining and/or FISH,
detected XMRV in a small percentage of stromal cells but
not in tumour cells, whereas others using similar techni-
ques reported XMRV predominantly in tumour cells
rather than stromal cells. In a recent study, Aloia and col-
leagues [3] employed HPLC purified proteins to raise the
antisera used for immunostaining, and were unable to find
any trace of XMRV at all in nearly 800 prostate tumours
analysed. They suggested that the positive immunostaining
described in earlier studies may have been due to the use
of non-specific antisera exhibiting cross-reactivity with
human cellular proteins [3].
Similar controversy surrounds claims of an association
between XMRV and chronic fatigue syndrome (CFS). In
a highly publicised study, Lombardi and colleagues
detected XMRV in 67% of CFS patients and 3.7% of
healthy controls by nested PCR [4]. Since Lombardi’s
initial publication, there have been numerous attempts
by other groups in several countries to confirm the link-
age between XMRV infection and CFS; but as yet none
have succeeded. Curiously, one study described PCR
detection of a second MLV (modified polytropic MLV),
but not XMRV itself, in the blood of some CFS patients
[5]. XMRV has also been sought in a variety of other
diseases including amyotrophic lateral sclerosis, multiple
sclerosis, autism, immunosuppression, rheumatoid
arthritis, fibromyalgia and paediatric idiopathic disease;
but all with negative results.
A number of recent publications have attempted to
explain these confusing and highly contradictory reports
by calling attention to the significant risk of false posi-
tive XMRV results due to laboratory contamination, and
to PCR contamination in particular. The considerable
potential for false positives arising from minute traces of
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has been clearly demonstrated as has the risk of erro-
neous results due to contamination from human tumour
cell lines infected with XMRV (e.g. 22Rv1) or other
xenotropic MLVs acquired by xenografting in mice [6].
Integration of XMRV into human chromosomes
Central to the hypothesis that XMRV is a genuine
human pathogen is the observation that it integrates
into the chromosomal DNA of prostate tumour tissues
[7,8]. Such integration of the cDNA copy of genomic
viral RNA to form the provirus is essential for retro-
viruses to establish productive infection. Given the
importance of this observation, we sought to examine
the authenticity of the XMRV integration sites that have
been reported to date.
T h eo n l yr e s e a r c hg r o u pd e s c ribing patient-derived
XMRV integration sites provides sequence data from 14
XMRV integration sites cloned from the prostatic
tumour tissues of 9 patients [GenBank: EU981800 to
GenBank: EU981813] [7,8]. Nucleotide BLAST searches
using each of the 14 integration site sequences against
the GenBank nr database revealed that 2 of the 14 inte-
gration sites [GenBank: EU981808 and GenBank:
EU981810], obtained from two different patients,
were identical to XMRV integration sites [GenBank:
GU816103 and GenBank: EU981678] respectively, which
were cloned from the experimentally infected human
tumour cell line, DU145 [8,9] in the same laboratories
(Figure 1A and 1B). Two mismatched nucleotides were
noted in the LTR region between EU981810 and
EU981678 (Figure 1B). These errors are possibly the
result of somatic mutation in the cell line during its
replication or the result of PCR error during amplifica-
tion. PCR error is not unlikely given the three step
nested PCR protocol and the non-proofreading enzyme
(Taq2000) used in the amplification of this integration
site (EU981810) from patient tissue [7].
Discussion
Current knowledge based on the analysis of several
thousand retroviral integration sites suggests that target
site selection is not primarily sequence-specific, although
different classes of retrovirus exhibit distinct genome
location biases [10]. HIV-1 for example appears to
favour integration into transcription units whereas MLV
tends to integrate near transcription start sites and CpG
islands. Both have a preference for gene dense regions.
Analysis of several hundred XMRV integration site
sequences [8,9] has revealed a preference for transcrip-
tion start sites, CpG islands, DNase-hypersensitive sites
and gene-dense regions as is typical for an MLV.
Although primary DNA sequence is not regarded as a
dominant factor in determining target site specificity, a
weak palindromic consensus sequence for XMRV inte-
gration sites (namely, 5’-CTVB where V is A, C or G
and B is C, G or T) has been identified [9]. With the
exception of a single early publication on avian sar-
coma-leukosis virus, which was refuted by later work
[10], sequencing studies of thousands of retroviral inte-
gration sites have to our knowledge never identified
exactly the same site twice. It therefore appears very
unlikely that the sites illustrated in Figure 1 are the
result of independent integrations into identical genomic
locations in a prostate tumour in vivo and an experi-
mentally infected cell line in vitro,o nt w os e p a r a t e
occasions.
We consider PCR based contamination to be the most
likely explanation for the identification of identical
A)
EU981808     CTCCTCAGAGTGATTGACTACCCAGCTCGGGGGTCTTTCAaaagcacaca
GU816103     ------------ATTGACTACCCAGCTCGGGGGTCTTTCAaaagcacaca
                         **************************************
EU981808     gatataagtgctgtcatatagtaaatgcctaaataaaagtgttttgtgta
GU816103     gatataagtgctgtcatatagtaaatacctaaataaaagtgttttgtgta
             ************************** ***********************
EU981808     gttttaatttatattctatttttcagaaacacaactaccatataaactga
GU816103     gttttaatttatattctatttttcagaaacacaactaccatataaactga
             **************************************************
EU981808     gagagtatttttatttctttgggattttacaaagagcaatttaccatttt
GU816103     gagagtatttttatttctttgggattttacaaagagcaatttaccatttt
             **************************************************
EU981808     tgaaaatcaggccattcacgggaacttgtagttccagctaatcgggaggc
GU816103     tgaaaatcaggccattcacgggaacttgtagttccagctaatcgggaggc
             **************************************************
EU981808     tgaggcaggagaatgacgtgaacctgggacgtgaacccatgagcttgcag
GU816103     tgaggcaggagaatgacgtgaacctgggacgtgaacccatgagcttgcag
             **************************************************
EU981808     tgagccagatcatgcctctgcactccagcctgggcaacagagcaagactc
GU816103     tgagccagatcatgcctctgcactccagcctgggcaacagagcaagactc
             **************************************************
EU981808     catctcaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
GU816103     catctcaaaaaaaaaaaaaaaaaaaaaaaaaa---- 
             ********************************
B)
EU981810     CTCCTCAGAGTGATTGACTACCCAGCTCGGGGGTCTTTCAatatgtttgg
EU981678     CTCCTCAGAGTAATTAACTACCCAGCTCGGGGGTCTTTCAatatgtttgg
             *********** *** **********************************
EU981810     ttaacacccttatcg 
EU981678     ttaacanccttatcg 
****** ********
Figure 1 Nucleotide alignments of XMRV integration site
sequences derived from patients’ prostate cancer tissues and
the experimentally infected human tumour cell line DU145.
Panel (A) shows the alignment of sequence EU981808 (patient
122-derived) and sequence GU816103 (DU145 cell line-derived).
Panel (B) shows the alignment of sequence EU981810 (patient
VP268-derived) and sequence EU981678 (DU145 cell line-derived).
The initial 169 nt segment of sequence EU981678 is not shown as it
includes a repeat within the XMRV sequence which is not covered
by the much shorter EU981810 sequence and is therefore
redundant for purposes of alignment. Upper case letters represent
the XMRV LTR sequence and lower case letters represent the
flanking human chromosomal sequence. Note that the viral 3’ ends
terminate with a conserved CA dinucleotide.
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sues and from the DU145 cells experimentally infected
with XMRV. It is noteworthy that the prostate tumour
tissue sites and the DU145 cell sites were cloned by the
same research group in the same laboratories [7-9] and
that the GU816103 sequence was derived from a clon-
ally amplified cell line [9]. The propensity for PCR con-
tamination is increased due to the unusual technique
used for cloning the prostate tissue-derived integration
sites which involved an extraordinary degree of PCR
amplification with 80 preliminary amplification cycles
followed by nested PCR consisting of 29 cycles and then
an additional 18 cycles [8]. PCR tubes were opened dur-
ing the procedure for the addition of fresh DNA poly-
merase after 40 cycles. Using such a technique would
entail a significant risk of direct or indirect contamina-
tion from experimentally infected DU145 cells, cellular
DNA, plasmids or PCR products that had been handled
in the same environment. No negative controls were
mentioned in the published method [8]. Although it
remains theoretically possible that contamination
occurred in the reverse direction, i.e. from the patient-
derived tumour tissue to the DU145 cell line, we con-
sider this to be exceedingly unlikely.
Whilst it is conceivable that the other 12 integration
sites apparently derived from prostatic tumour tissues
[7,8] are genuine patient-derived sequences, we suspect
that some or all of them may also be the result of con-
tamination with DNA from experimentally infected
DU145 cells. It is striking that there have been no inde-
pendent reports of patient-derived XMRV integration
sites nor have there been any descriptions of polytropic
or modified polytropic MLV integration sites in human
samples despite the apparent detection of these viruses
in CFS patients [5]. In conclusion, we believe that our
findings undermine a central component of the evidence
for XMRV being a human pathogen.
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